PE20141172A1 - Composiciones de nucleasa terapeuticas y metodos - Google Patents

Composiciones de nucleasa terapeuticas y metodos

Info

Publication number
PE20141172A1
PE20141172A1 PE2013002425A PE2013002425A PE20141172A1 PE 20141172 A1 PE20141172 A1 PE 20141172A1 PE 2013002425 A PE2013002425 A PE 2013002425A PE 2013002425 A PE2013002425 A PE 2013002425A PE 20141172 A1 PE20141172 A1 PE 20141172A1
Authority
PE
Peru
Prior art keywords
domain
nucleasa
methods
therapeutic compositions
dnase
Prior art date
Application number
PE2013002425A
Other languages
English (en)
Inventor
Jeffrey A Ledbetter
Martha Hayden-Ledbetter
Keith Elkon
Xizhang Sun
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of PE20141172A1 publication Critical patent/PE20141172A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/27—Endoribonucleases producing 3'-phosphomonoesters (3.1.27)
    • C12Y301/27005—Pancreatic ribonuclease (3.1.27.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)

Abstract

SE REFIERE A UNA MOLECULA DE NUCLEASA HIBRIDA QUE COMPRENDE: a) UN PRIMER DOMINIO DE NUCLEASA, QUE PRESENTA UNA RNASA A PANCREATICA HUMANA Y DNASA QUE SE SELECCIONA DEL GRUPO FORMADO POR UNA DNASA HUMANA DE TIPO 1, UNA DNASA HUMANA IL3, TREXI HUMANA ; Y b) UN DOMINIO FC MODIFICADO, DONDE EL PRIMER DOMINIO DE NUCLEASA ESTA ACOPLADO OPERATIVAMENTE AL DOMINIO FC, QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS QUE TIENE LAS MUTACIONES P238S, P331, SCCC, ENTRE OTROS. DICHA MOLECULA COMPRENDE UNA SECUENCIA DE AMINOACIDOS EN SEQ ID NO: 62,64, 78, 80, ENTRE OTROS. SE REFIERE TAMBIEN A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES.
PE2013002425A 2011-04-29 2012-04-27 Composiciones de nucleasa terapeuticas y metodos PE20141172A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161480961P 2011-04-29 2011-04-29
US201261617241P 2012-03-29 2012-03-29

Publications (1)

Publication Number Publication Date
PE20141172A1 true PE20141172A1 (es) 2014-09-22

Family

ID=47073103

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002425A PE20141172A1 (es) 2011-04-29 2012-04-27 Composiciones de nucleasa terapeuticas y metodos

Country Status (27)

Country Link
US (5) US10202588B2 (es)
EP (2) EP2704737B1 (es)
JP (5) JP6063450B2 (es)
KR (5) KR102428875B1 (es)
CN (2) CN103930127B (es)
AU (5) AU2012249360B2 (es)
BR (1) BR112013027547B1 (es)
CA (1) CA2834626A1 (es)
CL (1) CL2013003123A1 (es)
CO (1) CO6811815A2 (es)
CR (1) CR20130598A (es)
DK (1) DK2704737T3 (es)
DO (1) DOP2013000250A (es)
EA (1) EA201391585A1 (es)
EC (1) ECSP13013060A (es)
ES (1) ES2666303T3 (es)
HR (1) HRP20180564T1 (es)
HU (1) HUE038759T2 (es)
IL (4) IL300276B1 (es)
LT (1) LT2704737T (es)
MX (2) MX351953B (es)
NZ (1) NZ616989A (es)
PE (1) PE20141172A1 (es)
PL (1) PL2704737T3 (es)
SG (2) SG10201913930UA (es)
SI (1) SI2704737T1 (es)
WO (1) WO2012149440A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113528485A (zh) 2009-11-02 2021-10-22 华盛顿大学 治疗性核酸酶组合物和方法
IL300276B1 (en) 2011-04-29 2024-07-01 Univ Washington Therapeutic nuclease preparations and methods
WO2013114371A1 (en) * 2012-02-01 2013-08-08 Protalix Ltd. Dry powder formulations of dnase i
CA2898184A1 (en) 2013-01-16 2014-07-24 Emory University Cas9-nucleic acid complexes and uses related thereto
ES2759252T3 (es) 2013-10-31 2020-05-08 Resolve Therapeutics Llc Fusiones y métodos terapéuticos de nucleasa-albúmina
EP3110434B1 (en) * 2014-02-24 2018-09-19 Takeda GmbH Uti fusion proteins
WO2015191546A2 (en) * 2014-06-10 2015-12-17 The Board Of Regents Of The University Of Texas System Adp-ribose detection reagents
WO2016069889A1 (en) * 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
US10117911B2 (en) 2015-05-29 2018-11-06 Agenovir Corporation Compositions and methods to treat herpes simplex virus infections
WO2017044424A1 (en) 2015-09-08 2017-03-16 Theripion, Inc. Apoa-1 fusion polypeptides and related compositions and methods
EP3464367B1 (en) 2016-05-27 2020-09-09 AbbVie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
JP7308034B2 (ja) * 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー 最適化二重ヌクレアーゼ融合物および方法
WO2018136163A2 (en) 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
US10988746B2 (en) * 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
BR112021006737A2 (pt) * 2018-10-08 2021-07-13 Neutrolis, Inc. engenharia de enzimas dnase para fabricação e terapia
BR112021013096A2 (pt) * 2019-01-04 2022-04-19 Resolve Therapeutics, Llc Tratamento de doença de sjögren com proteínas de fusão de nuclease
JP2020136505A (ja) 2019-02-20 2020-08-31 株式会社Ｊｏｌｅｄ 半導体装置および表示装置
AU2021205976A1 (en) * 2020-01-11 2022-07-07 Yale University Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with DNAse1 and/or DNAse1L3 deficiency
AU2021288567A1 (en) * 2020-06-08 2023-02-09 Yale University Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections
CN112088903A (zh) * 2020-09-28 2020-12-18 武汉愔紫生物科技有限公司 一种大分子蛋白在抗菌抗病毒消毒剂中的应用
WO2022178090A2 (en) * 2021-02-19 2022-08-25 Theripion, Inc. Dnase fusion polypeptides and related compositions and methods
CN115595315A (zh) * 2021-06-28 2023-01-13 四川大学华西医院（Cn） 核糖核酸酶i在抑制疼痛的药物中的新用途

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5453269A (en) 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5559212A (en) 1988-04-06 1996-09-24 Alfacell Corporation Frog embryo and egg-derived tumor cell anti-proliferation protein
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5840840A (en) 1990-04-17 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Selective RNase cytotoxic reagents
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
GB9300686D0 (en) 1993-01-15 1993-03-03 Imp Cancer Res Tech Compounds for targeting
US20030108548A1 (en) 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
AU6873396A (en) 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
US6482626B2 (en) 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
AU3968897A (en) 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US7247302B1 (en) 1996-08-02 2007-07-24 Bristol-Myers Squibb Company Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
DK0932417T3 (da) 1996-10-17 2003-04-14 Immunomedics Inc Non-antigent toxinkonjugat og fusionsprotein af internaliserende receptorsystem
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20030054987A1 (en) 1997-06-16 2003-03-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020192659A1 (en) 1997-09-17 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5840296A (en) 1997-10-15 1998-11-24 Raines; Ronald T. Engineered cytotoxic ribonuclease A
US6280991B1 (en) 1997-10-15 2001-08-28 Wisconsin Alumni Research Foundation Engineered cytotoxic ribonclease
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US6239257B1 (en) 1998-12-30 2001-05-29 Alfacell Corporation Family of proteins belonging to the pancreatic ribonuclease a superfamily
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IL147270A0 (en) 1999-07-02 2002-08-14 Genentech Inc Fusion peptides comprising a peptide ligand domain and a multimerization domain
US6175003B1 (en) 1999-09-10 2001-01-16 Alfacell Corporation Nucleic acids encoding ribonucleases and methods of making them
WO2001026608A2 (en) 1999-10-14 2001-04-19 Ledbetter Jeffrey A Dna vaccines encoding antigen linked to a domain that binds cd40
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
IL157142A0 (en) 2001-01-29 2004-02-08 Idec Pharma Corp Modified antibodies and methods of use
KR20090010127A (ko) 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
JP4586310B2 (ja) 2001-07-04 2010-11-24 株式会社Ｉｈｉ セラミックス複合部材の製造方法
US20060040262A1 (en) 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
KR20040088572A (ko) 2002-03-01 2004-10-16 이뮤노메딕스, 인코오포레이티드 제거율 증강을 위한 양특이성 항체 점 돌연변이들
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP1539940A4 (en) 2002-06-14 2006-02-22 Wisconsin Alumni Res Found Ribonuclease zymogen CONSTRUCTION
US7425619B2 (en) 2002-08-14 2008-09-16 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
EP2345671B8 (en) 2002-09-27 2023-01-11 Xencor, Inc. Optimized fc variants and methods for their generation
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
JP4768439B2 (ja) 2002-10-15 2011-09-07 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
US20060263774A1 (en) 2002-11-01 2006-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB2395337B (en) 2002-11-14 2005-12-28 Gary Michael Wilson Warning Unit
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7067298B2 (en) 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US7666417B2 (en) * 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
CA2536408A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
BRPI0417916A (pt) 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
UA86605C2 (ru) 2004-01-12 2009-05-12 Аплайд Молекьюлер Иволюшн, Инк. Антитело, которое содержит вариант исходного человеческого fс-участка
US7544487B2 (en) 2004-02-13 2009-06-09 Immunomedics, Inc. Fusion proteins containing recombinant cytotoxic RNAses
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
US20080181892A1 (en) 2004-08-11 2008-07-31 Trubion Pharmaceuticals Binding Domain Fusion Protein
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
DE102005009219A1 (de) 2005-02-25 2006-08-31 Martin-Luther-Universität Halle-Wittenberg Ribonuclease-Tandemenzyme und Verfahren zu ihrer Herstellung
WO2006105062A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
EP1888649A2 (en) 2005-05-09 2008-02-20 GlycArt Biotechnology AG Antigen binding molecules having modified fc regions and altered binding to fc receptors
WO2006138458A1 (en) 2005-06-16 2006-12-28 Wisconsin Alumni Research Foundation Cytotoxic ribonuclease variants
JP2008546391A (ja) 2005-06-16 2008-12-25 ウイスコンシン アラムニ リサーチ ファンデーション 細胞傷害性リボヌクレアーゼ変異株
HUE026303T2 (hu) 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
US20080279850A1 (en) 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
JP4860702B2 (ja) 2005-10-21 2012-01-25 エフ．ホフマン−ラ ロシュ アーゲー ポリペプチドのリコンビナント発現のための方法
CN101466733A (zh) 2006-04-14 2009-06-24 特鲁比昂药品公司 包含免疫球蛋白铰链区和Fc效应子功能改变了的Fc区的结合蛋白
ATE547123T1 (de) * 2006-04-21 2012-03-15 Mab Factory Gmbh Antikörper-rnase-konjugat
GB0611444D0 (en) 2006-06-09 2006-07-19 Medical Res Council Technology Rnase H2 complex and genes therefor
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
EP1905841A1 (en) 2006-09-25 2008-04-02 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Trex1 as a marker for lupus erythematosus
WO2008131242A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
WO2008150485A2 (en) 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
KR20100044160A (ko) 2007-06-12 2010-04-29 와이어쓰 엘엘씨 항-ｃｄ20 치료 조성물 및 방법
BRPI0814060A2 (pt) 2007-07-06 2015-01-06 Trubion Pharmaceuticals Inc Peptídeos ligantes tendo um domínio de ligação específico disposto em c-terminal
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
US8067548B2 (en) 2007-07-26 2011-11-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
AU2008321074A1 (en) 2007-11-13 2009-05-22 Sapphire Energy, Inc. Production of Fc-fusion polypeptides in eukaryotic algae
DK2132228T3 (da) 2008-04-11 2011-10-10 Emergent Product Dev Seattle CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
AU2009296393A1 (en) * 2008-09-26 2010-04-01 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus
EP2334695B1 (en) 2008-10-01 2015-12-23 Quintessence Biosciences, Inc. Therapeutic ribonucleases
CN113528485A (zh) 2009-11-02 2021-10-22 华盛顿大学 治疗性核酸酶组合物和方法
TWI529163B (zh) 2011-01-25 2016-04-11 陶氏農業科學公司 用於製備４－胺基－５－氟－３－鹵素－６－（經取代之）吡啶甲酸酯的方法
WO2012115874A1 (en) 2011-02-23 2012-08-30 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
EP2678434B1 (en) 2011-02-25 2018-11-07 Recombinetics, Inc. Genetically modified animals and methods for making the same
LT3505528T (lt) 2011-04-21 2021-04-26 Glaxo Group Limited Hepatito b viruso (hbv) raiškos moduliacija
IL300276B1 (en) 2011-04-29 2024-07-01 Univ Washington Therapeutic nuclease preparations and methods
US20140178479A1 (en) 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
JP5782185B2 (ja) 2012-06-01 2015-09-24 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
EP2704737B1 (en) 2018-01-10
CA2834626A1 (en) 2012-11-01
AU2016201790B2 (en) 2017-11-30
EP2704737A2 (en) 2014-03-12
CN103930127B (zh) 2018-01-09
JP2023036998A (ja) 2023-03-14
KR20190090884A (ko) 2019-08-02
DOP2013000250A (es) 2014-01-31
US20150152399A1 (en) 2015-06-04
AU2022203877A1 (en) 2022-06-23
JP6063450B2 (ja) 2017-01-18
MX2021015735A (es) 2022-06-09
IL229074A0 (en) 2013-12-31
JP2017114854A (ja) 2017-06-29
SG10201913930UA (en) 2020-03-30
SI2704737T1 (en) 2018-06-29
AU2018201073B2 (en) 2019-12-05
KR20220112861A (ko) 2022-08-11
CN107964539A (zh) 2018-04-27
JP7212016B2 (ja) 2023-01-24
IL285985A (en) 2021-10-31
IL285985B2 (en) 2023-07-01
KR102161657B1 (ko) 2020-10-06
AU2018201073A1 (en) 2018-03-08
JP2019022505A (ja) 2019-02-14
AU2020201619C1 (en) 2022-10-06
IL285985B1 (en) 2023-03-01
CO6811815A2 (es) 2013-12-16
KR20200113028A (ko) 2020-10-05
LT2704737T (lt) 2018-06-11
AU2016201790A1 (en) 2016-04-14
HUE038759T2 (hu) 2018-11-28
US11034944B2 (en) 2021-06-15
CR20130598A (es) 2014-03-19
PL2704737T3 (pl) 2018-07-31
NZ616989A (en) 2016-03-31
KR20230156151A (ko) 2023-11-13
US10000745B2 (en) 2018-06-19
MX351953B (es) 2017-11-06
IL229074B (en) 2020-04-30
MX2013012612A (es) 2014-01-24
KR102006393B1 (ko) 2019-08-02
IL269020B (en) 2021-09-30
AU2020201619A1 (en) 2020-03-19
KR102596953B1 (ko) 2023-11-02
KR20140043353A (ko) 2014-04-09
ES2666303T3 (es) 2018-05-03
DK2704737T3 (en) 2018-04-23
AU2020201619B2 (en) 2022-03-10
WO2012149440A2 (en) 2012-11-01
CN107964539B (zh) 2022-06-28
HRP20180564T1 (hr) 2018-06-01
EA201391585A1 (ru) 2014-04-30
ECSP13013060A (es) 2015-03-31
BR112013027547B1 (pt) 2021-01-19
US20210395711A1 (en) 2021-12-23
BR112013027547A2 (pt) 2016-11-29
IL300276A (en) 2023-04-01
US8937157B2 (en) 2015-01-20
AU2012249360B2 (en) 2015-12-24
EP3449933A1 (en) 2019-03-06
WO2012149440A3 (en) 2014-05-15
SG194680A1 (en) 2013-12-30
AU2018201073C1 (en) 2020-06-04
AU2012249360A1 (en) 2013-04-11
KR102428875B1 (ko) 2022-08-05
EP2704737A4 (en) 2015-07-01
IL269020A (en) 2019-10-31
CN103930127A (zh) 2014-07-16
JP2014519809A (ja) 2014-08-21
JP2020203926A (ja) 2020-12-24
US20140044711A1 (en) 2014-02-13
US20140178379A1 (en) 2014-06-26
US10202588B2 (en) 2019-02-12
CL2013003123A1 (es) 2014-08-22
JP6762345B2 (ja) 2020-09-30
IL300276B1 (en) 2024-07-01
US20190119660A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
PE20141172A1 (es) Composiciones de nucleasa terapeuticas y metodos
PE20142168A1 (es) Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
CO6612271A2 (es) Anticuerpos anti-cd40
MX2023010178A (es) Conjugados de anticuerpo farmaco anti-cd70.
CR20140029A (es) Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
PE20230404A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
EA201200519A1 (ru) Стабилизированные жидкие и лиофилизированные композиции adamts13
AR094141A1 (es) Composiciones y metodos para proteinas de accion prolongada
EA201892339A2 (ru) Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания
BR112012024710A8 (pt) moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem
BR112014014591A2 (pt) processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
BRPI0909040A8 (pt) Derivados de azetidina e ciclobutano, seus usos, e composição
MX351414B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
PE20131065A1 (es) Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular
PE20161311A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
PE20141560A1 (es) Anticuerpo anti-epirregulina humanizado y agente terapeutico contra el cancer que comprende dicho anticuerpo como ingrediente activo
PE20161245A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
EA201390493A1 (ru) Человеческие антитела к онкостатину м и способы их применения

Legal Events

Date Code Title Description
FC Refusal